血清胱氨酸蛋白酶抑制剂C在高血压患者肾功能早期损伤诊断中的应用价值  

Application of cystatin C to diagnosis of early renal impairment in patients with hypertension

作　　者：王文武[1] 杨杰[1] 张真路[1] 

机构地区：[1]湖北省武汉亚洲心脏病医院检验中心,武汉430022

出　　处：《中华老年心脑血管病杂志》2007年第11期730-732,共3页Chinese Journal of Geriatric Heart,Brain and Vessel Diseases

摘　　要：目的探讨血清胱氨酸蛋白酶抑制剂C(胱抑素C)在诊断高血压患者肾功能早期损伤中的应用价值。方法将血清肌酐(Cr)和尿素氯(BUN)正常的645例患者,按尿微量蛋白(UMP)是否正常分为肾功能正常组(412例)和肾功能早期损伤组(233例);按患者血压状况将肾功能正常组又分为非高血压组(208例)和高血压组(204例),肾功能早期损伤组也分为非高血压组(109例)和高血压组(124例)。进行血清胱抑素C、UMP测定,并结合其血压进行分析。结果肾功能正常组中,高血压组患者的胱抑素C与非高血压组无显著性差异(P>0.05)。肾功能早期损伤组中,高血压组的胱抑素C值(1.06±0.23)mg/L比非高血压组高[(1.02±0.22)mg/L,P<0.05]。结论血清胱抑素C与UMP联合分析可以更有效地判断高血压是否对肾功能产生早期损伤。Objective To evaluate the applicability of serum cystatin C to diagnosis of early renal impairment in patients with hypertension. Methods Serum cystatin C and urine microprotein （UMP） were measured in 645 patients with normal serum Cr and BUN. The data and the blood pressure of the patients were analysed together. The patients were divided into normal renal function group（412 cases） and early renal impairment group（233 cases） according to their UMP results. Based on their blood pressure, the patients in the normal renal function group were further divided into normal blood pressure group（208 cases） and hypertension group（204 cases）,and the patients in the early renal impairment group were further divided into normal blood pressure group（109 cases） and hypertension group（124 cases）. Results When the renal function had no distinguishable impairment,cystatin C had no significant statistical difference between the hypertension group and normal blood pressure group（ P 〉0.05）. When the renal function had early impairment,the mean of cystatin C in the group with hypertension[（1.06±0.23） mg/L）] was higher than that in the group with normal blood pressure[（1. 02±0. 22） mg/L, P %0. 05]. Conclusion Analysis of serum cystatin C and UMP together would be helpful to estimating the early renal impairment of patients with hypertension effectively.

关 键 词：高血压 肾病 尿素 半胱氨酸蛋白酶抑制剂 

分 类 号：R544.1[医药卫生—心血管疾病]